Preview

Научно-практическая ревматология

Расширенный поиск

Новые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018)

https://doi.org/10.14412/1995-4484-2019-133-141

Полный текст:

Аннотация

Статья посвящена новым рекомендациям EULAR 2018 г. по ведению пациентов с болезнью/синдромом Бехчета (ББ), которые включают 5 принципов и 10 конкретных рекомендаций, касающихся лечения различных органных поражений. Рассмотрены методология их создания, а также нерешенные вопросы ведения пациентов с ББ, которые планируется исследовать в будущем.

Об авторах

Т. А. Лисицына
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А



З. С. Алекберова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А



Р. Г. Голоева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

115522, Москва, Каширское шоссе, 34А



Список литературы

1. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behcet disease. Ann Rheum Dis. 2008;67:1656-62. doi: 10.1136/ard.2007.080432

2. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet's syndrome. Ann Rheum Dis. 2018 Jun;77(6):808-18. doi: 10.1136/annrheumdis-2018-213225

3. Van der Heijde D, Aletaha D, Carmona L, et al. 2014 Update of the EULAR standardised operating procedures for EULARendorsed recommendations. Ann Rheum Dis. 2015;74:8-13. doi: 10.1136/annrheumdis-2014-206350

4. Aktulga E, Altac M, Müftüoglu A, et al. A double blind study of colchicine in Behcet's disease. Haematologica. 1980;65:399-402.

5. Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum. 2001;44:2686-92. doi: 10.1002/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H

6. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behcet's disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19:542-9. doi: 10.1007/s10165-009-0200-2

7. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med Overseas Ed. 1990;322:281-5. doi: 10.1056/NEJM199002013220501

8. Hamuryudan V, Mat C, Saip S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443-50. doi: 10.7326/0003-4819-128-6-199803150-00004

9. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467-71. doi: 10.1001/archderm.138.4.467

10. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98-105.

11. Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet's syndrome – a phase 2, placebo-controlled study. N Engl J Med Overseas Ed. 2015;372:1510-8. doi: 10.1056/NEJMoa1408684

12. Tasli L, Mat C, De Simone C, et al. Lactobacilli lozenges in the management of oral ulcers of Behcet's syndrome. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S83-6.

13. Sharquie KE, Najim RA, Abu-Raghif AR. Dapsone in Behcet's disease: a double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267-79. doi: 10.1111/j.1346-8138.2002.tb00263.x

14. Mumcu G, Inanc N, Еzdemir FT, et al. Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behcet's disease. Int J Dermatol. 2013;52:1561-6. doi: 10.1111/ijd.12144

15. Grayson PC, Yazici Y, Merideth M, et al. Treatment of mucocutaneous manifestations in Behcet's disease with anakinra: a pilot open-label study.Arthritis Res Ther. 2017;19:69. doi: 10.1186/s13075-017-1222-3

16. Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drugresistant Behcet's disease: a case series. Clin Rheumatol. 2015;34:1293-301. doi: 10.1007/s10067-013-2443-8

17. Emmi G, Talarico R, Lopalco G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behcet's disease: a multicenter retrospective study. Clin Rheumatol. 2016;35:1281-6. doi: 10.1007/s10067-015-3004-0

18. Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120:777-87. doi: 10.1016/j.ophtha.2012.09.040

19. Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. Rheumatology. 2013;52:1923-4. doi: 10.1093/rheumatology/ket130

20. Cantarini L, Lopalco G, Vitale A, et al. Paradoxical mucocutaneous flare in a case of Behcet's disease treated with tocilizumab. Clin Rheumatol. 2015;34:1141-3. doi: 10.1007/s10067-014-2589-z

21. Mirouse A, Barete S, Monfort J-B, et al. Ustekinumab for Behcet's disease. J Autoimmun. 2017;82:41-6. doi: 10.1016/j.jaut.2017.05.002

22. BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20(3 Suppl 4):136-43.

23. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241-3. doi: 10.1136/bjo.76.4.241

24. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989;1:1093-6. doi: 10.1016/S0140-6736(89)92381-7

25. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 2005;52:2478-84. doi: 10.1002/art.21231

26. Tugal-Tutkun I, Güney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol. 2006;244:1692-5. doi: 10.1007/s00417-006-0346-y

27. Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91:335-9. doi: 10.1136/bjo.2006.101550

28. Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology. 2007;46:1161-4. doi: 10.1093/rheumatology/kem101

29. Krause L, Altenburg A, Pleyer U, et al. Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol. 2008;35:896-903.

30. Gueudry J, Wechsler B, Terrada C, et al. Long-term efficacy and safety of low-dose interferon alpha-2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol. 2008;146:837-44. doi: 10.1016/j.ajo.2008.08.038

31. Sobaci G, Erdem U, Durukan AH, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology. 2010;117:1430-5. doi: 10.1016/j.ophtha.2009.11.022

32. Deuter CM, Zierhut M, Möhle A, et al. Long-term remission after cessation of interferon-γtreatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum. 2010;62:2796-805. doi: 10.1002/art.27581

33. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol. 2010;94:284-8. doi: 10.1136/bjo.2009.158840

34. Yamada Y, Sugita S, Tanaka H, et al. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment. Br J Ophthalmol. 2011;95:205-8. doi: 10.1136/bjo.2009.168856

35. Onal S, Kazokoglu H, Koc A, et al. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol. 2011;129:288-94. doi: 10.1001/archophthalmol.2011.3

36. Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Behcet's disease using infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S58-63.

37. Keino H, Okada AA, Watanabe T, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy. Br J Ophthalmol. 2011;95:1245-50. doi: 10.1136/bjo.2010.194464

38. Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Behcet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012;6:5-12. doi: 10.2147/BTT.S27343

39. Okada AA, Goto H, Ohno S, et al. Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Arch Ophthalmol. 2012;130(5):592-8. doi: 10.1001/archophthalmol.2011.2698

40. Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behcet's disease. Ocul Immunol Inflamm. 2012;20:198-202. doi: 10.3109/09273948.2012.670360

41. Al Rashidi S, Al Fawaz A, Kangave D, et al. Long-term clinical outcomes in patients with refractory uveitis associated with Behcet disease treated with infliximab. Ocul Immunol Inflamm. 2013;21:468-74. doi: 10.3109/09273948.2013.779727

42. Kawaguchi T, Kawazoe Y, Kamoi K, et al. Clinical course of patients with Behcet's uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol. 2014;58:75-80. doi: 10.1007/s10384-013-0283-3

43. Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the longterm efficacy and safety of infliximab treatment for uveitis in Behcet's disease: a multicenter study. Ophthalmology. 2014;121:1877-84. doi: 10.1016/j.ophtha.2014.04.042

44. Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF-therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients. Rheumatology. 2014;53:2223-31. doi: 10.1093/rheumatology/keu266

45. Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67-74. doi: 10.1016/j.jaut.2015.06.005

46. Jaffe GJ, Dick AD, Brеzin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med Overseas Ed. 2016;375:932-43. doi: 10.1056/NEJMoa1509852

47. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18:226-32. doi: 10.3109/09273948.2010.483314

48. Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behcet's disease: experience in 19 patients. Rheumatology. 2012;51:1825-31. doi: 10.1093/rheumatology/kes130

49. Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behcet's uveitis: a retrospective long-term followup study. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S58-62.

50. Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in severe Behcet's disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheum. 2017;69:2380-5. doi: 10.1002/art.40235

51. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, doublemasked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183-92. doi: 10.1016/S0140-6736(16)31339-3

52. Grekas D, Nikolaidis P, Karamouzis M, et al. Effects of azathioprine on ciclosporin metabolism. Nephron. 1992;60:489. doi: 10.1159/000186816

53. Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with Behcet's disease uveitis: an international, randomized, double-masked, placebo-controlled study and openlabel extension study. Ocul Immunol Inflamm. 2018;25:1-11. doi: 10.1080/09273948.2017.1421233

54. Ohguro N, Yamanaka E, Otori Y, et al. Repeated intravitreal triamcinolone injections in Behcet disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol. 2006;141:218-20. doi: 10.1016/j.ajo.2005.08.013

55. Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behcet disease. J Ocul Pharmacol Ther. 2007;23:395-401. doi: 10.1089/jop.2007.0015

56. Park UC, Park JH, Yu HG. Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behcet disease. Ocul Immunol Inflamm. 2014;22:27-33. doi: 10.3109/09273948.2013.829109

57. Seyahi E, Cakmak OS, Tutar B, et al. Clinical and ultrasonographic evaluation of lower-extremity vein thrombosis in Behcet syndrome: an observational study. Medicine. 2015;94:e1899. doi: 10.1097/MD.0000000000001899

58. Tascilar K, Melikoglu M, Ugurlu S, et al. Vascular involvement in Behcet's syndrome: a retrospective analysis of associations and the time course. Rheumatology. 2014;53:2018-22. doi: 10.1093/rheumatology/keu233

59. Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Behcet’s syndrome: Effects of anti-TNF treatment. Semin Arthritis Rheum. 2015;45:369-73. doi: 10.1016/j.semarthrit.2015.06.008

60. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behcet disease: a series of 47 patients. Medicine 2012;91:35-48. doi: 10.1097/MD.0b013e318242ff37

61. Le Thi Huong D, Wechsler B, Papo T, et al. Arterial lesions in Behcet's disease. A study in 25 patients. J Rheumatol. 1995;22:2103-13.

62. Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Behcet disease: a series of 101 patients. Medicine. 2012;91:18-24. doi: 10.1097/MD.0b013e3182428126

63. Park M-C, Hong B-K, Kwon HM, et al. Surgical outcomes and risk factors for postoperative complications in patients with Behcet's disease. Clin Rheumatol. 2007;26:1475-80. doi: 10.1007/s10067-006-0530-9

64. Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and longterm outcome of gastrointestinal involvement in Behcet's syndrome: a strobecompliant observational study from a dedicated multidisciplinary center. Medicine. 2016;95:e3348. doi: 10.1097/MD.0000000000003348

65. Jung YS, Hong SP, Kim TI, et al. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease. J Clin Gastroenterol. 2012;46:e38-e45. doi: 10.1097/MCG.0b013e3182431d56

66. Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease.Inflamm Bowel Dis. 2012;18:750-7. doi: 10.1002/ibd.21757

67. Hatemi I, Hatemi G, Pamuk ON, et al. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S129-37.

68. Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behcet's disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833-8. doi: 10.1097/MIB.0b013e31828f19c9

69. Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behcet's disease. Clin Gastroenterol Hepatol. 2015;13:940-8. doi: 10.1016/j.cgh.2014.08.042

70. Giardina A, Ferrante A, Ciccia F, et al. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. Rheumatol Int. 2011;31:33-7. doi: 10.1007/s00296-009-1213-z

71. Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285-90. doi: 10.1002/art.23345

72. Borhani Haghighi A, Safari A, Nazarinia MA, et al. Infliximab for patients with neuro-Behcet's disease: case series and literature review. Clin Rheumatol. 2011;30:1007-12. doi: 10.1007/s10067-011-1726-1

73. Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Behcet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3:e258. doi: 10.1212/NXI.0000000000000258

74. Al-Araji ASA, Saip S. Treatment of NeuroBehcet's disease with infliximab: an international multi-centre case-series of 18 patients. Clin Exp Rheumatol. 2010;28(Suppl 60):S119.

75. Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum. 2015;44:472-5. doi: 10.1016/j.semarthrit.2014.08.004

76. Yazici H, Ugurlu S, Seyahi E. Behcet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43:275-80. doi: 10.1007/s12016-012-8319-x


Для цитирования:


Лисицына Т.А., Алекберова З.С., Голоева Р.Г. Новые рекомендации по ведению пациентов с болезнью/синдромом Бехчета (EULAR, 2018). Научно-практическая ревматология. 2019;57(2):133-141. https://doi.org/10.14412/1995-4484-2019-133-141

For citation:


Lisitsyna T.A., Alekberova Z.S., Goloeva R.G. New guidelines for the management of patients with Behcet's disease/syndrome (EULAR, 2018). Rheumatology Science and Practice. 2019;57(2):133-141. (In Russ.) https://doi.org/10.14412/1995-4484-2019-133-141

Просмотров: 153


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)